iShares Biotechnology ETF
IBB
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 50 Hudson Yards New York NY United States of America 10001
- IPO Date
- Feb 12, 2001
- CIK
- 0001100663
- Website
- ishares.com
- Similar Companies
- Business
- iShares Biotechnology ETF (IBB) is an exchange-traded fund that seeks to track the investment results of the NYSE Biotechnology Index, comprising U.S.-listed equities engaged in the biotechnology sector, including companies focused on research, development, and production of therapeutic treatments, biotechnology tools, and systems. The ETF employs a physical replication strategy, investing at least 80% of its assets in index securities across all market capitalizations with modified market-cap weighting, subject to position caps of 8% for the top five holdings and 4% for others; it may also allocate up to 20% to cash equivalents, options, swaps, and other instruments. Managed by BlackRock Fund Advisors with an expense ratio of 0.44%, IBB provides diversified exposure to approximately 214 holdings, primarily in biotechnology (over 80%), life sciences tools and services, and pharmaceuticals, targeting institutional and retail investors seeking sector-specific growth. Launched on February 5, 2001, and headquartered in Wilmington, Delaware as part of iShares Trust domiciled in the United States, the ETF operates primarily on the NASDAQ exchange with global accessibility through BlackRock's distribution network. Prior to June 21, 2021, the fund was named iShares Nasdaq Biotechnology ETF and tracked the NASDAQ Biotechnology Index before transitioning to the NYSE Biotechnology Index. It distributes qualified dividends quarterly and is issued and distributed by BlackRock Investments LLC. Recent developments include sustained sector momentum in 2025, with IBB surging approximately 35% over the six months ending November 20, driven by merger and acquisition activity, FDA approvals, lower interest rates, and strong deal flow among holdings like Merck's $10 billion acquisition of Verona Pharma. Year-to-date through late 2025, the ETF has gained 23.6%, outperforming broader markets amid biotech resurgence, with top holdings such as Vertex Pharmaceuticals, Gilead Sciences, and Amgen comprising significant weights. No major fund-level structural changes, funding rounds, or new product launches have been reported since the 2021 index shift, though portfolio rebalancing occurs quarterly and full reconstitution annually in December.